Journal of Substance Abuse Treatment
Volume 34, Issue 2 , Pages 224-233 , March 2008

Economic costs of drug abuse: Financial, cost of illness, and services

Received 27 January 2006 ,Revised 19 March 2007 ,Accepted 5 April 2007.

References 

  1. Alemi F, Haack M, Holifield L, Claudio Y, Haqqi K. Unit cost of counseling and patients length of stay in a residential drug treatment setting. Journal of Mental Health Policy and Economics. 2002;5:103–107
  2. Alemi F, Taxman F, Doyon V, Thanner M, Baghi H. Activity based costing of probation with and without substance abuse treatment: A case study. Journal of Mental Health Policy and Economics. 2004;7:51–57
  3. Alexandre PK, Roebuck MC, French MT, Barry M. The cost of residential addiction treatment in public housing. Journal of Substance Abuse Treatment. 2003;24:285–290
  4. Andin-Sobocki P, Rehm J. Cost of addiction in Europe. European Journal of Neurology. 2005;12(Suppl. 1):28–33
  5. Ballard CL, Shoven JB, Whaley J. General equilibrium computation of the marginal welfare costs taxes in the United States. American Economic Review. 1987;77:11–23
  6. Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: Service utilization and costs. Journal of Nervous and Mental Disease. 1993;181:227–232
  7. Brent RJ. The tax implications of cost shifting in cost–benefit analysis in mental health. Applied Economics. 2003;35:943–950
  8. Calhoun BC, Watson PT. The cost of maternal cocaine abuse: I. Perinatal cost. Obstetrics and Gynecology. 1991;78:731–734
  9. Cartwright WS. Cost–benefit and cost-effectiveness analysis of drug abuse treatment services. Evaluation Review. 1998;22:609–636
  10. Cartwright WS. Cost–benefit analysis of drug treatment services: Review of the literature. Journal of Mental Health Policy and Economics. 2000;3:11–26
  11. Cartwright WS, Ingster LM. A patient-based analysis of drug disorder diagnoses in the Medicare population. Health Care Financing Review. 1993;15:89–101
  12. Chiu TT, Vaughn AJ, Carzoli RP. Hospital costs for cocaine-exposed infants. Journal of the Florida Medical Association. 1990;77:897–900
  13. Conover CJ, Ettner SL, Weaver M, Flynn PM, Porto JV. Economic evaluations of HIV treatment and health research with people diagnosed with HIV infection and co-occurring mental health and substance use disorders. AIDS Care. 2004;16(Suppl. 1):S121–S136
  14. Cruze AM, Harwood HJ, Kristiansen P, Collins JJ, Jones DC. Economic costs to society of alcohol and drug abuse and mental illness—1997. Research Triangle Park: Research Triangle Institute; 1981;
  15. Daley M, Argeriou M, McCarty D, Callahan JJ, Shepard DS, Williams CN. The impact of substance abuse treatment modality on birth weight and health care expenditures. Journal of Psychoactive Drugs. 2001;33:57–66
  16. Deschenes EP, Anglin MD, Speckart G. Narcotics addiction: Related criminal careers, social and economic costs. Journal of Substance Abuse. 1991;7:383–411
  17. Fenoglio P, Parel V, Kopp P. The social cost of alcohol, tobacco and illicit drugs in France, 1997. European Addiction Research. 2003;9:18–28
  18. Fox K, Merrill JC, Chang HH, Califano JA. Estimating the costs of substance abuse to the Medicaid hospital care program. American Journal of Public Health. 1995;85:48–54
  19. French MT, Mauskopf JA, Teague JL, Roland EJ. Estimating the dollar value of health outcomes from drug-abuse interventions. Medical Care. 1996;34:890–910
  20. Garcia-Altes A, Olle JM, Antonanzas F, Colom J. The social cost of illegal drug consumption in Spain. Addiction. 2002;97:1145–1153
  21. Gold MR. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996;
  22. Goldman HH, Frank RG, Burnam MA, Huskamp HA, Ridgely MS, Normand SL, et al. Behavioral health insurance parity for federal employees. New England Journal of Medicine. 2006;354:1378–1386
  23. Goodman AC, Nishiura E, Humphreys RS. Cost and usage impacts of treatment initiation: A comparison of alcoholism and drug abuse treatments. Alcoholism—Clinical and Experimental Research. 1997;21:931–938
  24. Goodman AC, Nishiura E, Hankin JR. Short term drug abuse treatment costs and utilization: A multi-employer analysis. Medical Care. 1998;36:1214–1227
  25. Gorsky RD, MacGowan RJ, Swanson NM, DelGado BP. Prevention of HIV infection in drug abusers: A cost analysis. Preventive Medicine. 1995;24:3–8
  26. Hardy AM, Rauch K, Echenberg D, Morgan WM, Curran JW. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. Journal of the American Medical Association. 1986;255:209–211
  27. Harwood HJ, Fountain D, Fountain G. Economic cost of alcohol and drug abuse in the United States, 1992: A report. Addiction. 1999;94:631–635
  28. Harwood HJ, Fountain D, Livermore G. Economic cost of alcohol and drug abuse in the United States, 1992: A report. Addiction. 1999;94:631–635
  29. Harwood HJ, Hubbard RL, Collins JJ, Rachal JV. The costs of crime and the benefits of drug abuse treatment: A cost–benefit analysis using TOPS data. NIDA Research Monograph. 1988;86:209–235
  30. Harwood HJ, Napelitano DM, Kristiansen PL, Collins JJ. Economic costs to society of alcohol and drug abuse and mental illness: 1980. Research Triangle Park, NC: Research Triangle Institute; 1984;
  31. Healy A, Knapp M, Asten J, Gossop M, Marsden J, Stewart D, et al. Economic burden of drug dependency—Social costs incurred by drug users at intake to the National Treatment Outcome Research Study. British Journal of Psychiatry. 1998;173:160–165
  32. Hellinger FJ. Forecasting the personal medical care costs of AIDS from 1988 through 1991. Public Health Reports. 1988;103:309–319
  33. Hellinger FJ. National forecasts of the medical care costs of AIDS: 1988–1992. Inquiry. 1988;25:469–484
  34. Hodgson TA, Meiners MR. Cost-of-illness methodology: A guide to current practices and procedures. Milbank Memorial Fund Quarterly. Health and Society. 1982;60:429–462
  35. Holder HD, Blose JO. The reduction of health care costs associated with alcoholism treatment: A 14-year longitudinal study. Journal of Studies on Alcohol. 1992;53:293–302
  36. Holder HD, Cisler RA, Longabaugh R, Stout RL, Treno AJ, Zweben A. Alcoholism treatment and medical care costs from Project MATCH. Addiction. 2000;95:999–1013
  37. Johnson BD, Goldstein PJ, Preble E, Schmeidler J, Lipton DS, Spunt B, et al. Taking care of business: The economics of crime by heroin abusers. Lexington: Lexington Books; 1985;
  38. Joyce T, Racine AD, Mocan N. The consequences and costs of maternal substance-abuse in New-York-City—A pooled time-series, cross-section analysis. Journal of Health Economics. 1992;11:297–314
  39. Kleiman MA. “Economic cost” measurements, damage minimization and drug abuse control policy. Addiction. 1999;94:638–641
  40. Laffont J-J, Mortimort D. The theory of incentives. Princeton: Princeton University Press; 2002;
  41. Lennox RD, Scott-Lennox JA, Holder HD. Substance abuse and family illness: Evidence from health care utilization and cost-offset research. Journal of Mental Health Administration. 1992;19:83–95
  42. Little AD. Social costs of drug abuse. Cambridge: A. D. Little Co.; 1975;
  43. Liu LY. Economic costs of alcohol and drug abuse in Texas—2000. Austin: Texas Commission on Alcohol and Drug Abuse; 2003;(pamphlet)
  44. Mark TL, Coffey RM. What drove private health insurance spending on mental health and substance abuse care, 1992-1999. Health Affairs. 2003;22:165–172
  45. Mark TL, Coffey RM, McKusick DR, Harwood H, King E, Bouchery E, et al. National Estimates of Expenditures for Mental Health Services and Substance Abuse Treatment, 1991-2001. SAMHSA Publication No. SMA 05-3999 Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005;
  46. Melek SP, Pyensen BS. Premium estimates for substance abuse parity for commercial health insurance products. Report prepared for the Coalition for Nondiscriminatroy Coverage of Addiction Treatment. Denver: Milliman & Robertson; 1997;September 2, 1997 http://ncadi.samhsa.gov/workplace/insur/default.aspx
  47. Mena M, Corvalan S, Bedregal P. Health care expenses among the offspring of cocaine base paste consumers. Revista Medica de Chile. 2002;130:1241–1248
  48. Needle R, Brown P, Lavee Y, Su S, Doherty W. Costs and consequences of drug use: A comparison of health care utilization and social–psychological consequences for clinical and nonclinical adolescents and their families. International Journal of the Addictions. 1988;23:1125–1143
  49. Norton EC, Zarkin GA, Calingaert B, Bradley CJ. The effect of maternal substance abuse on the cost of neonatal care. Inquiry—The Journal of Health Care Organization Provision and Financing. 1996;33:247–257
  50. Office on National Drug Control Policy . The economic cost of drug abuse in the untied states, 1992–1998 (rep. no. NCJ-190636). Washington, DC: Executive Office of the President; 2001;
  51. Parthasarathy S, Mertens J, Moore C, Weisner C. Utilization and cost impact of integrating substance abuse treatment and primary care. Medical Care. 2003;41:357–367
  52. Parthasarathy S, Weisner C, Hu TW, Moore C. Association of outpatient alcohol and drug treatment with health care utilization and cost: Revisiting the offset hypothesis. Journal of Studies on Alcohol. 2001;62:89–97
  53. Phibbs CS, Bateman DA, Schwartz RM. The neonatal costs of maternal cocaine use. Journal of the American Medical Association. 1991;266:1521–1526
  54. Ray GT, Collin F, Lieu T, Fireman B, Colby CJ, Quesenberry CP, et al. The cost of health conditions in a health maintenance organization. Medical Care Research and Review. 2000;57:92–109
  55. Reuter P. Are calculations of the economic costs of drug abuse either possible or useful?. Addiction. 1999;94:635–638
  56. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug-abuse and mental-illness, 1985 and 1988. Public Health Reports. 1991;106:280–292
  57. Rice DP, Kelman S, Miller LS, Dunmeyer S. The economic costs of alcohol and drug abuse and mental illness, 1985 (rep. no. DHHS publication no. ADM 90-1694). Washington, DC: U.S. Government Printing Office; 1990;
  58. Rosenbach M, Lake T, Young C, Conroy W, Quinn B, Ingels J, et al. Effects of the Vermont mental health and substance abuse parity law [rep. no. DHHS publ. no. (SMA) 03-3822]. Rockville, MD: Center for Mental Health Services, SAMHSA; 2003;
  59. Rosenbach ML. Utilization and cost of drug abuse treatment under Medicaid: An in-depth study of Washington state. In:  Denmead G,  Rouse BA editor. NIDA services research monograph (NIN publ. no. 94-3543). Rockville, MD: National Institute on Drug Abuse; 1994;p. 51–94
  60. Rufener BL, Rachal JV, Cruze AM. Management effectiveness measures for NIDA drug abuse treatment programs: Volume I. Cost benefit analysis. Rockville, MD: National Institute on Drug Abuse; 1997;
  61. Rufener BL, Rachal JV, Cruze AM. Managment effectiveness measures for NIDA drug abuse treatment programs: Volume II. Costs to society of drug abuse. Rockville, MD: National Institute on Drug Abuse; 1997;
  62. Rydell SP, Everingham SS. Controlling cocaine, supply versus demand programs. Santa Monica: RAND; 1994;
  63. Saunders SA, Democratis J, Martin J, Macfarlane IA. Intravenous drug abuse and Type 1 diabetes: Financial and healthcare implications. Diabetic Medicine. 2004;21:1269–1273
  64. Schoenbaum M, Zhang W, Sturm R. Costs and utilization of substance abuse care in a privately insured population under managed care. Psychiatric Services. 1998;49:1573–1578
  65. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Journal of Medical Practice Management. 1988;3:234–241
  66. Sing M, Hill S, Smolkin S, Heiser N. The costs and effects of parity for mental health and substance abuse insurance benefits. Rockville, MD: US Department of Health and Huamn Services Publication No. SMA 98-3205; 1998;http://mentalhealth.samhsa.gov/publications/alpubs/Mc99-80/prtyfnix.asp
  67. Sturm R, Goldman W, McCulloch J. Mental health and substance abuse parity: A case study of Ohio's state employee program. Journal of Mental Health Policy and Economics. 1998;1:129–134
  68. Sturm R, Zhang W, Schoenbaum M. How expensive are unlimited substance abuse benefits under managed care?. Journal of Behavioral Health Services & Research. 1999;26:203–210
  69. Weisner C, Mertens J, Parthasarathy S, Moore C, Hunkeler EM, Hu T, et al. The outcome and cost of alcohol and drug treatment in an HMO: Day hospital versus traditional outpatient regimens. Health Services Research. 2000;35:791–812
  70. Xie X, Rehrn J, Single E, Robson L, Paul J. The economic costs of illicit drug use in Ontario, 1992. Health Economics. 1998;7:81–85

 Please do not quote without permission. The views expressed are solely those of the author and are not the responsibility of his former or current organizational affiliations.

PII: S0740-5472(07)00107-9

doi: 10.1016/j.jsat.2007.04.003

Journal of Substance Abuse Treatment
Volume 34, Issue 2 , Pages 224-233 , March 2008

Article Tools